This weekend the US Food and Drug Administration (FDA) has informed that the impact of the COVID-19 pandemic and the reallocation of staff is leading to an even greater prolonged timeline for reviews of submissions. Anders Hultman, CEO of AroCell, commenting the FDA...
As previously informed, at the end of 2019, IDL Biotech signed a cooperation agreement with the Chinese company Zecen Biotech, regarding automation of the tumor marker TPS® on all Zecen Biotech's instruments. The development project has proceeded very well and the...
(In Swedish)
IDL Biotech wants to focus on rapid diagnostic tests and automated assays of its tumor markers. By licensing the platform ELISA to Beckman Coulter, we can focus our resources on streamlining and developing the other platforms, said Gunnar Wahlberg, CEO of IDL...
In recent years IDL Biotech has been working on developing a rapid test to detect lung cancer, under the project name MonoTotal® Rapid. However, further development will instead focus on creating a rapid test for breast cancer. Read the article here (Swedish)
Quantification of Thymidine Kinase 1 in serum with AroCell TK 210 ELISA is now validated for use on an open automation platform for ELISA. This enhances the application and use of the assay. We have now validated AroCell TK 210 ELISA for use on an automation platform,...
In 2019, IDL Biotech submitted a so-called Pre-submission request to the US FDA (United States Food and Drug Administration) this was done to ensure the future approval of UBC® Rapid, the companys rapid diagnostic test for bladder cancer. As of now, the company is...
A new Redeye interview with Michael Brobjer, AroCell CEO, commenting interim report for the second quarter of 2020. See the interview on Redeye's website.
A publication presented in Entropy shows the value of UBC® Rapid Read the press release here and here
IDL Biotech has appointed Subyung Park as Business Development Manager Asia with a focus on the product TUBEX® TF. Read the press release here
